Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2868 Injection in Subjects With Advanced Malignant Tumors
Latest Information Update: 07 Jun 2024
At a glance
- Drugs TQB 2868 (Primary)
- Indications Tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 29 Apr 2022 Status changed from not yet recruiting to recruiting.
- 28 Jan 2022 New trial record